Physician profile
Thomas H Li
NPI 1649224403
$3,897.31
in general payments reported to CMS, 2019-2025
29 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $293 · 2021: $801 · 2022: $1,092 · 2023: $572 · 2024: $259 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $560.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $399.50 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $385.77 | 2019-2024 | Evenity, Prolia |
| Abbvie INC. | $281.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $259.74 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $227.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.11 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $196.93 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $184.23 | 2020-2022 | |
| Amarin Pharma, INC. | $126.58 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $118.85 | 2022 | |
| Exact Sciences Corporation | $102.36 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $95.94 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $95.04 | 2021-2022 | |
| Radius Health, INC. | $92.16 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $87.21 | 2021 | |
| Sanofi-Aventis U.S. LLC | $71.91 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $70.63 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| E.R. Squibb & Sons, L.L.C. | $61.03 | 2021-2022 | |
| Abbott Laboratories | $46.89 | 2023-2024 | Freestyle Libre 2 |
| Astellas Pharma US INC | $43.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $35.01 | 2019 | |
| Endo Pharmaceuticals INC. | $24.43 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.82 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $22.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.13 | 2023 | Quviviq |
| Allergan, INC. | $20.91 | 2020 | |
| Alfasigma USA, INC. | $16.92 | 2022 | |
| Evoke Pharma, INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.